PL2558095T3 - Związek organiczny, przeznaczony do stosowania w leczeniu raka wątroby - Google Patents
Związek organiczny, przeznaczony do stosowania w leczeniu raka wątrobyInfo
- Publication number
- PL2558095T3 PL2558095T3 PL11715691T PL11715691T PL2558095T3 PL 2558095 T3 PL2558095 T3 PL 2558095T3 PL 11715691 T PL11715691 T PL 11715691T PL 11715691 T PL11715691 T PL 11715691T PL 2558095 T3 PL2558095 T3 PL 2558095T3
- Authority
- PL
- Poland
- Prior art keywords
- treatment
- organic compound
- liver cancer
- liver
- cancer
- Prior art date
Links
- 201000007270 liver cancer Diseases 0.000 title 1
- 208000014018 liver neoplasm Diseases 0.000 title 1
- 150000002894 organic compounds Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32493610P | 2010-04-16 | 2010-04-16 | |
| EP11715691.9A EP2558095B1 (en) | 2010-04-16 | 2011-04-14 | Organic compound for use in the treatment of liver cancer |
| PCT/EP2011/055906 WO2011128403A1 (en) | 2010-04-16 | 2011-04-14 | Organic compound for use in the treatment of liver cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2558095T3 true PL2558095T3 (pl) | 2019-06-28 |
Family
ID=44260208
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL11715691T PL2558095T3 (pl) | 2010-04-16 | 2011-04-14 | Związek organiczny, przeznaczony do stosowania w leczeniu raka wątroby |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US8741903B2 (pl) |
| EP (1) | EP2558095B1 (pl) |
| JP (1) | JP2013525291A (pl) |
| KR (1) | KR20130073873A (pl) |
| CN (1) | CN102844031A (pl) |
| AU (1) | AU2011239999B2 (pl) |
| BR (1) | BR112012026289A2 (pl) |
| CA (1) | CA2793779A1 (pl) |
| DK (1) | DK2558095T3 (pl) |
| ES (1) | ES2707625T3 (pl) |
| HU (1) | HUE042535T2 (pl) |
| MX (1) | MX2012012051A (pl) |
| PL (1) | PL2558095T3 (pl) |
| PT (1) | PT2558095T (pl) |
| RU (1) | RU2012148710A (pl) |
| TR (1) | TR201819653T4 (pl) |
| WO (1) | WO2011128403A1 (pl) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
| LT3495367T (lt) | 2012-06-13 | 2021-02-25 | Incyte Holdings Corporation | Pakeistieji tricikliniai junginiai, kaip fgfr inhibitoriai |
| WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| LT2986610T (lt) | 2013-04-19 | 2018-04-10 | Incyte Holdings Corporation | Bicikliniai heterociklai, kaip fgfr inhibitoriai |
| WO2015142367A1 (en) * | 2014-03-17 | 2015-09-24 | Incuron, Llc | Compositions and methods of treating liver cancer |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
| SG11201706287PA (en) | 2015-02-20 | 2017-09-28 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| MX2020011718A (es) | 2018-05-04 | 2021-02-15 | Incyte Corp | Formas solidas de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr) y procesos para prepararlas. |
| ES3061844T3 (en) | 2018-05-04 | 2026-04-07 | Incyte Corp | Salts of an fgfr inhibitor |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| US12122767B2 (en) | 2019-10-01 | 2024-10-22 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| TWI891666B (zh) | 2019-10-14 | 2025-08-01 | 美商英塞特公司 | 作為ｆｇｆｒ抑制劑之雙環雜環 |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| CA3163875A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| WO2021113462A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Derivatives of an fgfr inhibitor |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| TW202304459A (zh) | 2021-04-12 | 2023-02-01 | 美商英塞特公司 | 包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法 |
| JP2024522189A (ja) | 2021-06-09 | 2024-06-11 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤としての三環式ヘテロ環 |
| EP4352060A1 (en) | 2021-06-09 | 2024-04-17 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4361727B2 (ja) | 2000-09-11 | 2009-11-11 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | チロシンキナーゼインヒビターとしてのキノリノン誘導体 |
| CA2496164C (en) | 2002-08-23 | 2010-11-09 | Chiron Corporation | Benzimidazole quinolinones and uses thereof |
| WO2005082340A2 (en) * | 2004-02-20 | 2005-09-09 | Chiron Corporation | Modulation of inflammatory and metastatic processes |
| US20060183750A1 (en) * | 2005-01-27 | 2006-08-17 | Chiron Corporation | Treatment of metastasized tumors |
| CN101146538A (zh) * | 2005-01-27 | 2008-03-19 | 诺华疫苗和诊断公司 | 转移瘤的治疗 |
| EP2270000B1 (en) | 2005-05-23 | 2015-07-29 | Novartis AG | Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts |
| PE20091628A1 (es) | 2008-03-19 | 2009-11-19 | Novartis Ag | Formas cristalinas y dos formas solvatadas de sales de acido lactico de 4-amino-5-fluoro-3-[5-(4-metilpiperazin-1-il)-1h-benzimidazol-2-il]quinolin-2(1h)-ona |
-
2011
- 2011-04-14 EP EP11715691.9A patent/EP2558095B1/en active Active
- 2011-04-14 HU HUE11715691A patent/HUE042535T2/hu unknown
- 2011-04-14 KR KR1020127026836A patent/KR20130073873A/ko not_active Ceased
- 2011-04-14 WO PCT/EP2011/055906 patent/WO2011128403A1/en not_active Ceased
- 2011-04-14 MX MX2012012051A patent/MX2012012051A/es active IP Right Grant
- 2011-04-14 CA CA2793779A patent/CA2793779A1/en not_active Abandoned
- 2011-04-14 BR BR112012026289A patent/BR112012026289A2/pt not_active Application Discontinuation
- 2011-04-14 PL PL11715691T patent/PL2558095T3/pl unknown
- 2011-04-14 AU AU2011239999A patent/AU2011239999B2/en not_active Ceased
- 2011-04-14 PT PT11715691T patent/PT2558095T/pt unknown
- 2011-04-14 DK DK11715691.9T patent/DK2558095T3/en active
- 2011-04-14 JP JP2013504276A patent/JP2013525291A/ja active Pending
- 2011-04-14 RU RU2012148710/15A patent/RU2012148710A/ru unknown
- 2011-04-14 CN CN2011800191319A patent/CN102844031A/zh active Pending
- 2011-04-14 US US13/641,668 patent/US8741903B2/en active Active
- 2011-04-14 ES ES11715691T patent/ES2707625T3/es active Active
- 2011-04-14 TR TR2018/19653T patent/TR201819653T4/tr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUE042535T2 (hu) | 2019-07-29 |
| TR201819653T4 (tr) | 2019-01-21 |
| AU2011239999A1 (en) | 2012-11-08 |
| US20130123272A1 (en) | 2013-05-16 |
| EP2558095A1 (en) | 2013-02-20 |
| CA2793779A1 (en) | 2011-10-20 |
| EP2558095B1 (en) | 2018-10-24 |
| ES2707625T3 (es) | 2019-04-04 |
| US8741903B2 (en) | 2014-06-03 |
| DK2558095T3 (en) | 2019-01-14 |
| KR20130073873A (ko) | 2013-07-03 |
| AU2011239999B2 (en) | 2014-04-03 |
| WO2011128403A1 (en) | 2011-10-20 |
| RU2012148710A (ru) | 2014-05-27 |
| JP2013525291A (ja) | 2013-06-20 |
| MX2012012051A (es) | 2012-11-22 |
| BR112012026289A2 (pt) | 2016-07-12 |
| CN102844031A (zh) | 2012-12-26 |
| PT2558095T (pt) | 2019-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE042535T2 (hu) | Szerves vegyület a májrák kezelésére | |
| HRP20181185T1 (hr) | Inhibitori ibat za liječenje bolesti jetre | |
| ZA201207574B (en) | Phytocannabinoids in the treatment of cancer | |
| ZA201300567B (en) | Methods and compositions for liver cancer therapy | |
| IL251083A0 (en) | Compounds and preparations for the treatment of cancer | |
| GB201115711D0 (en) | Phyto-cannabinoids for use in the treatment of cancer | |
| HUE043569T2 (hu) | Vegyületek rák kezelésére | |
| IL231835A0 (en) | Pyrrolopyrimidine compounds for cancer treatment | |
| SG10201508495VA (en) | Combination treatment of cancer | |
| PT2605764E (pt) | Composições para o tratamento de cancro | |
| IL222958A0 (en) | Cancer treatment | |
| IL227719A0 (en) | Combined treatment for prostate cancer using oligonucleotides against clusterin and 90hsp inhibitors | |
| GB201718726D0 (en) | Phytocannabinoids in the treatment of cancer | |
| PL2460509T3 (pl) | Kompozycja do leczenia brodawek | |
| GB201011073D0 (en) | Composition for the treatment of acne vulgaris | |
| GB201010588D0 (en) | Cancer treatment | |
| HK1174257A (en) | Phytocannabinoids in the treatment of cancer | |
| HUP1000688A2 (en) | Use of trifluoro-phthalimides in the treatment of cancer | |
| GB201019034D0 (en) | Treatment for tumors | |
| GB201000771D0 (en) | Compound for therapy | |
| GB201017356D0 (en) | Combination treatment of cancer | |
| GB201020513D0 (en) | Cancer therapy |